General Information of Drug (ID: DMLCTBP)

Drug Name
VTX-2337
Synonyms
Motolimod; 926927-61-9; VTX-2337; Motolimod (VTX-2337); UNII-WP6PY72ZH3; VTX-378; VTX 2337; WP6PY72ZH3; AK171372; Motolimod [USAN:INN]; Motolimod (USAN/INN); SCHEMBL254984; GTPL9026; CHEMBL3301618; KS-00000SZB; DTXSID10239107; MolPort-039-136-930; EX-A1102; BCP16667; ZINC34946588; s7161; AKOS025289797; SB16930; DB12303; HY-13773; KB-146010; J3.657.311B; D10716; 2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide
Indication
Disease Entry ICD 11 Status REF
Allergy 4A80-4A85 Discontinued in Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 458.6
Logarithm of the Partition Coefficient (xlogp) 3.8
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C28H34N4O2
IUPAC Name
2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide
Canonical SMILES
CCCN(CCC)C(=O)C1=CC2=C(C=C(C=C2)C3=CC=C(C=C3)C(=O)N4CCCC4)N=C(C1)N
InChI
InChI=1S/C28H34N4O2/c1-3-13-31(14-4-2)28(34)24-17-23-12-11-22(18-25(23)30-26(29)19-24)20-7-9-21(10-8-20)27(33)32-15-5-6-16-32/h7-12,17-18H,3-6,13-16,19H2,1-2H3,(H2,29,30)
InChIKey
QSPOQCXMGPDIHI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
16049404
ChEBI ID
CHEMBL3301618
CAS Number
926927-61-9
UNII
WP6PY72ZH3
DrugBank ID
DB12303
TTD ID
D0H3JF
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 8 (TLR8) TT8CWFK TLR8_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01666444) VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Array BioPharma (Drug: Motolimod / VTX2337).